MRZ-9547, also known as (R)-phenylpiracetam, (R)-phenotropil, or (R)-fonturacetam, is a selective dopamine reuptake inhibitor (IC50Tooltip half-maximal inhibitory concentration = 14.5 μM) that was developed by Merz Pharma.

[4][5][7] The drug was under development for the treatment of fatigue associated with Parkinson's disease and was in phase 1 clinical trials for this indication in June 2014.

[1] There was also interest in MRZ-9547 for treatment of fatigue in people with depression and other conditions, but this was not pursued.

[2][5] Similarly to other dopamine reuptake inhibitors and related agents, MRZ-9547 has been found to have pro-motivational effects in animals and to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine.

[5][9] This drug article relating to the nervous system is a stub.